FDA — authorised 14 October 2020
- Application: BLA761169
- Marketing authorisation holder: REGENERON PHARMACEUTICALS
- Indication: Type 1 - New Molecular Entity
- Status: approved
🇺🇸 Inmazeb in United States
FDA authorised Inmazeb on 14 October 2020
Marketing authorisation
Inmazeb in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Immunology approved in United States
Frequently asked questions
Is Inmazeb approved in United States?
Yes. FDA authorised it on 14 October 2020.
Who is the marketing authorisation holder for Inmazeb in United States?
REGENERON PHARMACEUTICALS holds the US marketing authorisation.